



## Clinical trial results:

### An open-label study to characterize the pharmacokinetics and pharmacodynamics of mepolizumab administered subcutaneously in children from 6 to 11 years of age with severe eosinophilic asthma

#### Summary

EudraCT number	2014-002666-76
Trial protocol	GB Outside EU/EEA
Global end of trial date	31 January 2018

#### Results information

Result version number	v3 (current)
This version publication date	09 August 2018
First version publication date	23 June 2017
Version creation reason	

#### Trial information

##### Trial identification

Sponsor protocol code	200363
-----------------------	--------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	GlaxoSmithKline
Sponsor organisation address	980 Great West Road, Brentford, Middlesex, United Kingdom,
Public contact	GSK Response Center, GlaxoSmithKline, 1 866-435-7343,
Scientific contact	GSK Response Center, GlaxoSmithKline, 1 866-435-7343,

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMEA-000069-PIP02-10
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	31 January 2018
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	31 January 2018
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

Pharmacokinetic/Pharmacodynamic Phase (Part A):

- To characterize the pharmacokinetics of mepolizumab administered subcutaneously to subjects aged 6 to 11 years old with severe eosinophilic asthma
- To characterize the pharmacodynamics of mepolizumab administered subcutaneously to subjects aged 6 to 11 years old with severe eosinophilic asthma

Long-Term Safety / Long-Term Pharmacodynamic Phase (Part B):

- To assess the long-term (52 weeks) safety and tolerability of mepolizumab when administered subcutaneously to subjects aged 6 to 11 years old with severe eosinophilic asthma

Protection of trial subjects:

Numbing cream or spray was permitted at the site of injection and rescue medications (salbuterol/albuterol) are available to the participant throughout the study.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	25 August 2015
Long term follow-up planned	Yes
Long term follow-up rationale	Ethical reason
Long term follow-up duration	2 Years
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Japan: 7
Country: Number of subjects enrolled	Poland: 11
Country: Number of subjects enrolled	United Kingdom: 17
Country: Number of subjects enrolled	United States: 9
Worldwide total number of subjects	44
EEA total number of subjects	28

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	43
Adolescents (12-17 years)	1
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

This was a multi-center, open-label study to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of mepolizumab 40 or 100 milligrams (mg) subcutaneously administered to participants with severe eosinophilic asthma aged 6-11 years. This study consisted of two parts: Part A and Part B.

### Pre-assignment

Screening details:

Part A consisted of pre-screening/ screening/ run-in, treatment, and Follow-up. Part B was long-term treatment and Follow-up phase. A total of 44 participants were screened and 36 were enrolled in Part A. Of which, 30 participants continued on treatment in Part B. Study was conducted in 4 countries (Japan, Poland, United Kingdom and United States).

### Period 1

Period 1 title	Part A (20 weeks)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Part A: Mepolizumab 40 mg SC

Arm description:

Participants with bodyweight < 40 kilogram (kg) received 0.4 milliliter (mL) of reconstituted mepolizumab subcutaneously every four weeks, in upper arm or thigh directly from the investigator or designee, under medical supervision. Participant's weight at Week 0 (Visit 2) was considered to select dosage in Part A. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product.

Arm type	Experimental
Investigational medicinal product name	Mepolizumab 40 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants with bodyweight < 40 kg received 0.4 mL of reconstituted mepolizumab subcutaneously every four weeks, in upper arm or thigh. Investigational product was administered subcutaneously by the investigator or designee, under medical supervision. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product.

<b>Arm title</b>	Part A: Mepolizumab 100 mg SC
------------------	-------------------------------

Arm description:

Participants with bodyweight  $\geq$  40 kg received 1.0 mL of reconstituted mepolizumab subcutaneously every four weeks, in upper arm or thigh directly from the investigator or designee, under medical supervision. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product. On investigator discretion, injected volume was split between two injection sites and was given as 2 injections of 0.5 mL each if required.

Arm type	Experimental
Investigational medicinal product name	Mepolizumab 100 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants with bodyweight  $\geq$  40 kg received 1.0 mL of reconstituted mepolizumab subcutaneously

every four weeks, in upper arm or thigh. Investigational product was administered subcutaneously by the investigator or designee, under medical supervision. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product.

Number of subjects in period 1 <sup>[1]</sup>	Part A: Mepolizumab 40 mg SC	Part A: Mepolizumab 100 mg SC
	Started	26
Completed	22	10
Not completed	4	0
Physician decision	1	-
AE of Asthma Exacerbation	1	-
Consent withdrawn by subject	2	-

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: A total of 44 participants were screened and 36 were enrolled to treatment in Part A.

## Period 2

Period 2 title	Part B (From Week 20 and up to Week 80)
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

## Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Part B: Mepolizumab 40 mg SC

Arm description:

Participants with bodyweight < 40 kg received 0.4 mL of reconstituted mepolizumab subcutaneously every four weeks, in upper arm or thigh directly from the investigator or designee, under medical supervision. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product.

Arm type	Experimental
Investigational medicinal product name	Mepolizumab 40 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants with bodyweight < 40 kg received 0.4 mL of reconstituted mepolizumab subcutaneously every four weeks, in upper arm or thigh. Investigational product was administered subcutaneously by the investigator or designee, under medical supervision. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product.

<b>Arm title</b>	Part B: Mepolizumab 100 mg SC
------------------	-------------------------------

Arm description:

Participants with bodyweight >= 40 kg received 1.0 mL of reconstituted mepolizumab subcutaneously

every four weeks, in upper arm or thigh directly from the investigator or designee, under medical supervision. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product. On investigator discretion, injected volume was split between two injection sites and was given as 2 injections of 0.5 mL each if required.

Arm type	Experimental
Investigational medicinal product name	Mepolizumab 100 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Subcutaneous use

**Dosage and administration details:**

Participants with bodyweight  $\geq 40$  kg received 1.0 mL of reconstituted mepolizumab subcutaneously every four weeks, in upper arm or thigh. Investigational product was administered subcutaneously by the investigator or designee, under medical supervision. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product.

<b>Arm title</b>	Part B: Mepolizumab 40/100 mg SC
------------------	----------------------------------

**Arm description:**

Participants received either 0.4 mL or 1.0 mL of reconstituted mepolizumab depending upon the bodyweight, administered subcutaneously every four weeks, in upper arm or thigh directly from the investigator or designee, under medical supervision. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product. Participants enrolled to  $<40$  kg at Visit 9 (Week 20) were summarized in the 40/100 mg SC group if they had weight  $\geq 40$  kg at any subsequent visit.

Arm type	Experimental
Investigational medicinal product name	Mepolizumab 40 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Subcutaneous use

**Dosage and administration details:**

Participants with bodyweight  $< 40$  kg received 0.4 mL of reconstituted mepolizumab subcutaneously every four weeks, in upper arm or thigh. Investigational product was administered subcutaneously by the investigator or designee, under medical supervision. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product.

Investigational medicinal product name	Mepolizumab 100 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Subcutaneous use

**Dosage and administration details:**

Participants with bodyweight  $\geq 40$  kg received 1.0 mL of reconstituted mepolizumab subcutaneously every four weeks, in upper arm or thigh. Investigational product was administered subcutaneously by the investigator or designee, under medical supervision. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product.

<b>Number of subjects in period 2<sup>[2]</sup></b>	Part B: Mepolizumab 40 mg SC	Part B: Mepolizumab 100 mg SC	Part B: Mepolizumab 40/100 mg SC
Started	16	10	4
Completed	15	10	4
Not completed	1	0	0
Protocol deviation	1	-	-

---

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: A total of 44 participants were screened, of which 36 were enrolled to receive treatment in Part A.

## Baseline characteristics

### Reporting groups

Reporting group title	Part A: Mepolizumab 40 mg SC
Reporting group description:	
Participants with bodyweight < 40 kilogram (kg) received 0.4 milliliter (mL) of reconstituted mepolizumab subcutaneously every four weeks, in upper arm or thigh directly from the investigator or designee, under medical supervision. Participant's weight at Week 0 (Visit 2) was considered to select dosage in Part A. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product.	
Reporting group title	Part A: Mepolizumab 100 mg SC
Reporting group description:	
Participants with bodyweight >= 40 kg received 1.0 mL of reconstituted mepolizumab subcutaneously every four weeks, in upper arm or thigh directly from the investigator or designee, under medical supervision. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product. On investigator discretion, injected volume was split between two injection sites and was given as 2 injections of 0.5 mL each if required.	

Reporting group values	Part A: Mepolizumab 40 mg SC	Part A: Mepolizumab 100 mg SC	Total
Number of subjects	26	10	36
Age categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	8.0 ± 1.79	10.0 ± 1.33	-
Gender categorical Units: Subjects			
Female	6	5	11
Male	20	5	25
Race/Ethnicity, Customized Units: Subjects			
Central/South Asian Heritage (Her.)	1	0	1
Japanese Her.	6	1	7
Black or African American (B or Af Am)	4	3	7
White/Caucasian/European Her.	14	6	20
B or Af Am and White-White/Caucasian/European Her.	1	0	1

## End points

### End points reporting groups

Reporting group title	Part A: Mepolizumab 40 mg SC
-----------------------	------------------------------

Reporting group description:

Participants with bodyweight < 40 kilogram (kg) received 0.4 milliliter (mL) of reconstituted mepolizumab subcutaneously every four weeks, in upper arm or thigh directly from the investigator or designee, under medical supervision. Participant's weight at Week 0 (Visit 2) was considered to select dosage in Part A. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product.

Reporting group title	Part A: Mepolizumab 100 mg SC
-----------------------	-------------------------------

Reporting group description:

Participants with bodyweight  $\geq$  40 kg received 1.0 mL of reconstituted mepolizumab subcutaneously every four weeks, in upper arm or thigh directly from the investigator or designee, under medical supervision. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product. On investigator discretion, injected volume was split between two injection sites and was given as 2 injections of 0.5 mL each if required.

Reporting group title	Part B: Mepolizumab 40 mg SC
-----------------------	------------------------------

Reporting group description:

Participants with bodyweight < 40 kg received 0.4 mL of reconstituted mepolizumab subcutaneously every four weeks, in upper arm or thigh directly from the investigator or designee, under medical supervision. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product.

Reporting group title	Part B: Mepolizumab 100 mg SC
-----------------------	-------------------------------

Reporting group description:

Participants with bodyweight  $\geq$  40 kg received 1.0 mL of reconstituted mepolizumab subcutaneously every four weeks, in upper arm or thigh directly from the investigator or designee, under medical supervision. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product. On investigator discretion, injected volume was split between two injection sites and was given as 2 injections of 0.5 mL each if required.

Reporting group title	Part B: Mepolizumab 40/100 mg SC
-----------------------	----------------------------------

Reporting group description:

Participants received either 0.4 mL or 1.0 mL of reconstituted mepolizumab depending upon the bodyweight, administered subcutaneously every four weeks, in upper arm or thigh directly from the investigator or designee, under medical supervision. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product. Participants enrolled to <40 kg at Visit 9 (Week 20) were summarized in the 40/100 mg SC group if they had weight  $\geq$ 40 kg at any subsequent visit.

Subject analysis set title	Part A: Mepolizumab SC
----------------------------	------------------------

Subject analysis set type	Intention-to-treat
---------------------------	--------------------

Subject analysis set description:

Participants received mepolizumab 40 or 100 mg SC, depending on participant's bodyweight (40 mg for <40 kg and 100 mg for  $\geq$ 40 kg). Participants received 0.4 mL of reconstituted mepolizumab subcutaneously (for 40 mg dose) or 1.0 mL of reconstituted mepolizumab subcutaneously (for 100 mg dose) every four weeks, in upper arm or thigh directly from the investigator or designee, under medical supervision. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product.

Subject analysis set title	Part B: Mepolizumab 40 mg SC
----------------------------	------------------------------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

Subject analysis set description:

Participants with bodyweight < 40 kg received 0.4 mL of reconstituted mepolizumab subcutaneously every four weeks, in upper arm or thigh directly from the investigator or designee, under medical supervision. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product.

Subject analysis set title	Part B: Mepolizumab 100 mg SC
----------------------------	-------------------------------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

Subject analysis set description:

Participants with bodyweight  $\geq$  40 kg received 1.0 mL of reconstituted mepolizumab subcutaneously every four weeks, in upper arm or thigh directly from the investigator or designee, under medical

supervision. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product. On investigator discretion, injected volume was split between two injection sites and was given as 2 injections of 0.5 mL each if required.

Subject analysis set title	Part B: Mepolizumab 40/100 mg SC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received either 0.4 mL or 1.0 mL of reconstituted mepolizumab depending upon the bodyweight, administered subcutaneously every four weeks, in upper arm or thigh directly from the investigator or designee, under medical supervision. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product. Participants enrolled to <40 kg at Visit 9 (Week 20) were summarized in the 40/100 mg SC group if they had weight  $\geq$ 40 kg at any subsequent visit.

### Primary: Maximum plasma concentration (Cmax) of mepolizumab for Part A

End point title	Maximum plasma concentration (Cmax) of mepolizumab for Part A <sup>[1]</sup>
-----------------	--

End point description:

PK of mepolizumab was evaluated in participants using Cmax. PK samples were collected at pre-dose on Weeks 4 and 8; and at Weeks 9, 12, 16 and 20. Cmax was evaluated by population PK methods and mean and standard error from the final model has been tabulated. Estimates have been presented from the final model centered to mean bodyweights of 27 kg, 50 kg and 70 kg. Note the average bodyweight of 70kg (mean body weight observed in adults) was not investigated in the study. PK Population included all participants receiving at least one dose of mepolizumab beginning at Visit 2 (Week 0) and having at least one blood sample taken at Visit 3 (Week 4) or thereafter with measurable mepolizumab plasma concentration.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose on Weeks 4 and 8; Weeks 9, 12, 16 and 20 post-dose

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There are no statistical data to report.

End point values	Part A: Mepolizumab SC			
Subject group type	Subject analysis set			
Number of subjects analysed	36 <sup>[2]</sup>			
Units: Microgram (ug) per mL				
arithmetic mean (standard error)				
70 kg	12.8188 ( $\pm$ 0.7843)			
50 kg	16.3412 ( $\pm$ 0.6364)			
27 kg	10.1960 ( $\pm$ 0.3345)			

Notes:

[2] - PK Population

### Statistical analyses

No statistical analyses for this end point

### Primary: Area under concentration time curve to infinity (AUC [0-inf]) of mepolizumab for Part A

End point title	Area under concentration time curve to infinity (AUC [0-inf]) of mepolizumab for Part A <sup>[3]</sup>
-----------------	--

End point description:

PK of mepolizumab was evaluated in participants using AUC (0-inf). PK samples were collected at pre-dose on Weeks 4 and 8; and at Weeks 9, 12, 16 and 20. AUC (0-inf) was evaluated by population PK methods and mean and standard error from the final model has been tabulated. Estimates have been presented from the final model centered to mean bodyweights of 27 kg, 50 kg and 70 kg. Note the average bodyweight of 70kg (mean body weight observed in adults) was not investigated in the study.

End point type | Primary

End point timeframe:

Pre-dose on Weeks 4 and 8; Weeks 9, 12, 16 and 20 post-dose

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There are no statistical data to report.

End point values	Part A: Mepolizumab SC			
Subject group type	Subject analysis set			
Number of subjects analysed	36 <sup>[4]</sup>			
Units: Day*ug per mL				
arithmetic mean (standard error)				
70 kg	508.23 (± 41.8036)			
50 kg	675.20 (± 35.8980)			
27 kg	454.39 (± 15.8876)			

Notes:

[4] - PK Population

## Statistical analyses

No statistical analyses for this end point

## Primary: Terminal phase elimination half-life (t1/2) of mepolizumab during treatment period for Part A

End point title | Terminal phase elimination half-life (t1/2) of mepolizumab during treatment period for Part A<sup>[5]</sup>

End point description:

PK of mepolizumab was evaluated in participants using t1/2. PK samples were collected at pre-dose on Weeks 4 and 8; and at Weeks 9, 12, 16 and 20 post-dose. T1/2 was evaluated by population PK methods and mean and standard error from the final model has been tabulated. Estimates have been presented from the final model centered to mean bodyweights of 27 kg, 50 kg and 70 kg. Note the average bodyweight of 70kg (mean body weight observed in adults) was not investigated in the study.

End point type | Primary

End point timeframe:

Pre-dose on Weeks 4 and 8; Weeks 9, 12, 16 and 20 post-dose

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There are no statistical data to report.

<b>End point values</b>	Part A: Mepolizumab SC			
Subject group type	Subject analysis set			
Number of subjects analysed	36 <sup>[6]</sup>			
Units: Days				
arithmetic mean (standard error)				
70 kg	20.9583 (± 1.6520)			
50 kg	21.8420 (± 1.0999)			
27 kg	23.5582 (± 0.8406)			

Notes:

[6] - PK Population

## Statistical analyses

No statistical analyses for this end point

### Primary: Plasma Apparent Clearance (CL/F) of mepolizumab in Part A

End point title	Plasma Apparent Clearance (CL/F) of mepolizumab in Part A <sup>[7]</sup>
-----------------	--

End point description:

PK of mepolizumab was evaluated in participants using CL/F. PK samples were collected at pre-dose on Weeks 4 and 8; and at Weeks 9, 12, 16 and 20 post-dose. CL was evaluated by population PK methods and mean and standard error from the final model has been tabulated. Estimates have been presented from the final model centered to mean bodyweights of 27 kg, 50 kg and 70 kg. Note the average bodyweight of 70kg (mean body weight observed in adults) was not investigated in the study.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose on Weeks 4 and 8; Weeks 9, 12, 16 and 20 post-dose

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There are no statistical data to report.

<b>End point values</b>	Part A: Mepolizumab SC			
Subject group type	Subject analysis set			
Number of subjects analysed	36 <sup>[8]</sup>			
Units: Liter (L) per day				
arithmetic mean (standard error)				
70 kg	0.1968 (± 0.01618)			
50 kg	0.1481 (± 0.007874)			
27 kg	0.08803 (± 0.003078)			

Notes:

[8] - PK Population

## Statistical analyses

No statistical analyses for this end point

**Primary: Ratio to Baseline in absolute blood eosinophil count at Week 12 for Part A**

End point title	Ratio to Baseline in absolute blood eosinophil count at Week 12 for Part A <sup>[9]</sup>
-----------------	---

## End point description:

PD of mepolizumab was evaluated in participants using ratio to Baseline in absolute blood eosinophil count. Blood samples were collected at indicated time points. Baseline was defined as the latest value recorded prior to the first dose of mepolizumab. Ratio to Baseline was calculated as post-dose visit value/Baseline value. It was evaluated by Pharmacodynamic Eosinophils (PDe) Population which included all participants receiving at least one dose of mepolizumab beginning at Visit 2 (Week 0) and having at least one Part A blood sample evaluable for blood eosinophil count. Only those participants with data available at specific time point were analyzed.

End point type	Primary
----------------	---------

## End point timeframe:

Baseline and Week 12

## Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There are no statistical data to report.

End point values	Part A: Mepolizumab 40 mg SC	Part A: Mepolizumab 100 mg SC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	22 <sup>[10]</sup>	10 <sup>[11]</sup>		
Units: Ratio of eosinophils in blood				
geometric mean (confidence interval 95%)				
Ratio of eosinophils in blood	0.115 (0.067 to 0.196)	0.166 (0.087 to 0.318)		

## Notes:

[10] - PDe Population

[11] - PDe Population

**Statistical analyses**

No statistical analyses for this end point

**Primary: Number of participants with on treatment serious adverse events (SAEs) and non-SAEs for Part B**

End point title	Number of participants with on treatment serious adverse events (SAEs) and non-SAEs for Part B <sup>[12]</sup>
-----------------	--

## End point description:

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinemia are to be categorized as SAE. On-treatment SAEs and non-SAEs are defined as events occurring from the first Part B dose until 28 days following the last Part B dose. Safety Population includes all participants who received at least one dose of mepolizumab beginning at Visit 9.

End point type	Primary
----------------	---------

## End point timeframe:

From Week 20 up to Week 72

## Notes:

[12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There are no statistical data to report.

<b>End point values</b>	Part B: Mepolizumab 40 mg SC	Part B: Mepolizumab 100 mg SC	Part B: Mepolizumab 40/100 mg SC	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	16 <sup>[13]</sup>	10 <sup>[14]</sup>	4 <sup>[15]</sup>	
Units: Participants				
Any SAE	4	2	1	
Any non-SAE	15	8	4	

Notes:

[13] - Safety Population

[14] - Safety Population

[15] - Safety Population

### Statistical analyses

No statistical analyses for this end point

### Primary: Number of participants with positive anti-mepolizumab binding antibodies and neutralizing antibodies response for Part B

End point title	Number of participants with positive anti-mepolizumab binding antibodies and neutralizing antibodies response for Part B <sup>[16]</sup>
-----------------	--

End point description:

Blood sample were collected for the determination of anti-mepolizumab binding antibodies and neutralizing antibodies response in Part B at Weeks 44, 68 and 80 prior to study treatment administration. Participant was considered 'Positive' if they had at least one positive post-Baseline anti-drug antibody assay result. All Part B visits (including scheduled and unscheduled) post-Baseline were considered for Any-time Post-Baseline visit derivation. The number of participants with positive anti-mepolizumab binding antibodies and neutralizing antibodies response at Any Time Post Baseline has been presented. The neutralizing antibodies response results only presented for participants with positive anti-drug antibody assay.

End point type	Primary
----------------	---------

End point timeframe:

From Week 20 up to Week 80

Notes:

[16] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There are no statistical data to report.

<b>End point values</b>	Part B: Mepolizumab 40 mg SC	Part B: Mepolizumab 100 mg SC	Part B: Mepolizumab 40/100 mg SC	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	16 <sup>[17]</sup>	10 <sup>[18]</sup>	4 <sup>[19]</sup>	
Units: Participants				
Anti-drug antibody	0	0	0	
Neutralizing antibody	0	0	0	

Notes:

[17] - Safety Population

[18] - Safety Population

[19] - Safety Population

### Statistical analyses

No statistical analyses for this end point

### Primary: Change from Baseline in sitting systolic blood pressure (SBP) and diastolic

**blood pressure (DBP) for Part B**

End point title	Change from Baseline in sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) for Part B <sup>[20]</sup>
-----------------	---

End point description:

Sitting blood pressure measurements included SBP and DBP. Measurements were done pre-infusion/injection with the participant sitting, having rested in this position for at least 5 minutes before each reading. The Baseline was defined as the latest value recorded prior to the first dose of mepolizumab. Change from Baseline was defined as value at indicated time point minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Primary
----------------	---------

End point timeframe:

Baseline and Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 80

Notes:

[20] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There are no statistical data to report.

End point values	Part B: Mepolizumab 40 mg SC	Part B: Mepolizumab 100 mg SC	Part B: Mepolizumab 40/100 mg SC	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	16 <sup>[21]</sup>	10 <sup>[22]</sup>	4 <sup>[23]</sup>	
Units: Millimeter of mercury (mmHg)				
arithmetic mean (standard deviation)				
Sitting DBP, Week 24, n=16,9, 4	1.4 (± 4.22)	-0.9 (± 6.68)	-0.8 (± 3.59)	
Sitting DBP, Week 28, n=15,9, 3	5.7 (± 7.13)	1.6 (± 5.53)	-4.0 (± 7.00)	
Sitting DBP, Week 32, n=15,9,3	2.3 (± 5.65)	3.0 (± 7.37)	1.0 (± 12.49)	
Sitting DBP, Week 36, n=15,8,3	3.6 (± 4.73)	4.9 (± 11.14)	1.7 (± 8.62)	
Sitting DBP, Week 40, n=15,9,3	2.3 (± 8.40)	4.2 (± 6.82)	-3.7 (± 4.73)	
Sitting DBP, Week 44, n=15,9,3	1.4 (± 5.62)	6.2 (± 7.61)	3.7 (± 11.85)	
Sitting DBP, Week 48, n=15,9,3	3.5 (± 7.50)	4.1 (± 6.15)	8.7 (± 3.21)	
Sitting DBP, Week 52, n=15,9,3	3.5 (± 7.55)	1.4 (± 5.05)	-3.3 (± 9.61)	
Sitting DBP, Week 56, n=15,9,3	2.2 (± 8.47)	3.6 (± 7.14)	-0.3 (± 8.02)	
Sitting DBP, Week 60, n=15,9,3	0.8 (± 4.80)	6.3 (± 10.77)	-2.3 (± 8.08)	
Sitting DBP, Week 64, n=15,9,3	1.7 (± 3.48)	3.9 (± 8.12)	0.7 (± 3.06)	
Sitting DBP, Week 68, n=15,9,3	3.3 (± 7.08)	5.3 (± 7.60)	-2.0 (± 10.58)	
Sitting DBP, Week 72, n=15,10,4	2.5 (± 6.15)	5.4 (± 10.42)	0.5 (± 10.21)	
Sitting DBP, Week 80, n=12,9,2	1.3 (± 4.60)	7.4 (± 7.60)	0.5 (± 13.44)	
Sitting SBP, Week 24, n=16,9,4	3.3 (± 7.44)	-2.4 (± 13.87)	-6.3 (± 6.95)	
Sitting SBP, Week 28, n=15,9,3	9.3 (± 6.11)	-0.6 (± 13.47)	-1.0 (± 5.57)	
Sitting SBP, Week 32, n=15,9,3	2.9 (± 5.59)	5.6 (± 12.04)	-2.7 (± 16.50)	
Sitting SBP, Week 36, n=15,8,3	6.3 (± 9.13)	9.4 (± 11.84)	-1.3 (± 6.43)	
Sitting SBP, Week 40, n=15,9,3	5.5 (± 7.85)	4.6 (± 9.74)	-9.3 (± 12.22)	
Sitting SBP, Week 44, n=15,9,3	4.3 (± 8.50)	3.8 (± 8.32)	3.0 (± 9.54)	
Sitting SBP, Week 48, n=15,9,3	5.5 (± 8.25)	4.2 (± 11.09)	3.3 (± 11.68)	
Sitting SBP, Week 52, n=15,9,3	7.8 (± 7.19)	-1.2 (± 12.04)	-5.0 (± 17.32)	
Sitting SBP, Week 56, n=15,9,3	4.9 (± 7.81)	2.1 (± 10.33)	-9.7 (± 15.04)	
Sitting SBP, Week 60, n=15,9,3	5.7 (± 8.33)	2.3 (± 16.50)	-3.3 (± 17.62)	
Sitting SBP, Week 64, n=15,9,3	5.5 (± 7.98)	5.2 (± 12.09)	-1.3 (± 15.89)	
Sitting SBP, Week 68, n=15,9,3	8.6 (± 8.58)	5.6 (± 8.75)	4.3 (± 10.02)	
Sitting SBP, Week 72, n=15,10,4	6.4 (± 5.79)	2.7 (± 10.93)	-3.3 (± 9.22)	
Sitting SBP, Week 80, n=12,9,2	3.3 (± 4.33)	3.6 (± 11.82)	11.5 (± 0.71)	

Notes:

[21] - Safety Population

[22] - Safety Population

[23] - Safety Population

## Statistical analyses

No statistical analyses for this end point

### Primary: Change from Baseline in sitting pulse rate for Part B

End point title Change from Baseline in sitting pulse rate for Part B<sup>[24]</sup>

End point description:

Sitting pulse rate measurements were performed pre-infusion/injection with the participant sitting, having rested in this position for at least 5 minutes before each reading. The Baseline was defined as the latest value recorded prior to the first dose of mepolizumab in Part A. Change from Baseline was defined as value at indicated time point minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type Primary

End point timeframe:

Baseline and Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 80

Notes:

[24] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There are no statistical data to report.

End point values	Part B: Mepolizumab 40 mg SC	Part B: Mepolizumab 100 mg SC	Part B: Mepolizumab 40/100 mg SC	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	16 <sup>[25]</sup>	10 <sup>[26]</sup>	4 <sup>[27]</sup>	
Units: Beats per minute				
arithmetic mean (standard deviation)				
Sitting pulse rate, Week 24, n= 16, 9, 4	-3.8 (± 5.80)	4.3 (± 7.50)	7.0 (± 16.51)	
Sitting pulse rate, Week 28, n= 15, 9, 3	-7.0 (± 9.02)	2.7 (± 4.92)	1.7 (± 9.61)	
Sitting pulse rate, Week 32, n= 15, 9, 3	-4.8 (± 9.75)	4.7 (± 10.30)	-7.7 (± 12.01)	
Sitting pulse rate, Week 36, n= 15, 8, 3	-0.5 (± 11.30)	7.3 (± 12.28)	8.0 (± 7.00)	
Sitting pulse rate, Week 40, n= 15, 9, 3	-4.5 (± 10.84)	1.7 (± 14.04)	-4.0 (± 4.00)	
Sitting pulse rate, Week 44, n= 15, 9, 3	-0.7 (± 13.56)	3.4 (± 12.30)	4.0 (± 19.31)	
Sitting pulse rate, Week 48, n= 15, 9, 3	-2.3 (± 11.29)	-0.6 (± 5.64)	-3.0 (± 8.19)	
Sitting pulse rate, Week 52, n= 15, 9, 3	-1.3 (± 8.41)	-2.1 (± 9.03)	11.7 (± 4.16)	
Sitting pulse rate, Week 56, n= 15, 9, 3	-3.8 (± 8.90)	-1.9 (± 10.99)	-0.3 (± 6.66)	
Sitting pulse rate, Week 60, n= 15, 9, 3	-3.4 (± 11.18)	-1.0 (± 13.86)	6.3 (± 14.43)	
Sitting pulse rate, Week 64, n= 15, 9, 3	-2.0 (± 11.16)	5.0 (± 11.26)	8.3 (± 16.86)	
Sitting pulse rate, Week 68, n= 15, 9, 3	-0.9 (± 8.03)	-2.4 (± 9.18)	-4.3 (± 10.97)	
Sitting pulse rate, Week 72, n= 15, 10, 4	-5.3 (± 8.66)	-0.3 (± 14.21)	-6.0 (± 6.83)	
Sitting pulse rate, Week 80, n= 11, 9, 2	-2.5 (± 3.33)	2.1 (± 7.24)	13.0 (± 9.90)	

Notes:

[25] - Safety Population

[26] - Safety Population

[27] - Safety Population

## Statistical analyses

**Primary: Number of participants with any time change from Baseline relative to normal range in clinical chemistry parameters for Part B**

End point title	Number of participants with any time change from Baseline relative to normal range in clinical chemistry parameters for Part B <sup>[28]</sup>
-----------------	--

## End point description:

Blood samples were collected for analysis of alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), albumin, protein, bilirubin, creatinine, urate, direct bilirubin, calcium, carbon dioxide (CO<sub>2</sub>), chloride, glucose, potassium, sodium and urea. Baseline was defined as the latest value recorded prior to the first dose of mepolizumab in Part A. Change from Baseline was defined as value at indicated time point minus Baseline value. All Part B visits (scheduled and unscheduled) post-Baseline were considered for Any-time Post-Baseline visit derivation. If participant had at least one value for categories "To Low" and/or "To High" along with "To Normal or No Change" then participant was counted under "To Low" and/or "To High". If participant had values which belong only to "To Normal or No Change" then participant was counted under "To Normal or No Change" only. Any Time Post-Baseline values have been presented.

End point type	Primary
----------------	---------

## End point timeframe:

Baseline, from Week 20 and up to Week 72

## Notes:

[28] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There are no statistical data to report.

End point values	Part B: Mepolizumab 40 mg SC	Part B: Mepolizumab 100 mg SC	Part B: Mepolizumab 40/100 mg SC	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	16 <sup>[29]</sup>	10 <sup>[30]</sup>	4 <sup>[31]</sup>	
Units: Participants				
ALT; To Low	0	0	0	
ALT; To Normal or No Change	16	10	4	
ALT; To High	0	0	0	
Albumin; To Low	0	0	0	
Albumin; To Normal or No Change	15	10	4	
Albumin; To High	1	0	0	
ALP; To Low	0	0	0	
ALP; To Normal or No Change	16	10	4	
ALP; To High	0	0	0	
AST; To Low	0	0	0	
AST; To Normal or No Change	16	10	4	
AST; To High	0	0	0	
Bilirubin; To Low	0	0	0	
Bilirubin; To Normal or No Change	16	9	4	
Bilirubin; To High	0	1	0	
Calcium; To Low	0	0	0	
Calcium; To Normal or No Change	16	7	3	
Calcium; To High	0	3	1	
CO <sub>2</sub> ; To Low	6	3	3	
CO <sub>2</sub> ; To Normal or No Change	10	7	1	
CO <sub>2</sub> ; To High	0	0	0	
Chloride; To Low	0	0	0	
Chloride; To Normal or No Change	16	9	4	

Chloride; To High	0	1	0
Creatinine; To Low	2	2	0
Creatinine; To Normal or No Change	13	7	4
Creatinine; To High	1	1	0
Direct Bilirubin; To Low	0	0	0
Direct Bilirubin; To Normal or No	16	10	4
Direct Bilirubin; To High	0	0	0
GGT; To Low	0	0	0
GGT; To Normal or No Change	16	10	4
GGT; To High	0	0	0
Glucose; To Low	1	2	0
Glucose; To Normal or No Change	10	4	1
Glucose; To High	5	4	3
Potassium; To Low	0	1	0
Potassium; To Normal or No Change	16	9	4
Potassium; To High	0	0	0
Protein; To Low	0	0	0
Protein; To Normal or No Change	15	10	4
Protein; To High	1	0	0
Sodium; To Low	0	0	0
Sodium; To Normal or No Change	16	10	4
Sodium; To High	0	0	0
Urate; To Low	0	0	0
Urate; To Normal or No Change	16	10	4
Urate; To High	0	0	0
Urea; To Low	2	1	1
Urea; To Normal or No Change	14	9	3
Urea; To High	0	0	0

Notes:

[29] - Safety Population

[30] - Safety Population

[31] - Safety Population

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of participants with any time change from Baseline relative to normal range in hematology parameters for Part B

End point title	Number of participants with any time change from Baseline relative to normal range in hematology parameters for Part B <sup>[32]</sup>
-----------------	--

End point description:

Blood samples were collected for analysis of basophils, eosinophils, leukocyte, monocyte, neutrophils, lymphocyte, platelets, mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), hemoglobin (Hgb), mean corpuscular volume (MCV), erythrocytes, hematocrit, and reticulocytes/erythrocytes (Ret/Ery). Baseline was defined as the latest value recorded prior to first dose of mepolizumab in Part A. Change from Baseline was defined as value at indicated time point minus Baseline value. All Part B visits (scheduled and unscheduled) post-Baseline were considered for Any-time Post-Baseline visit derivation. If participant had at least one value for categories "To Low" and/or "To High" along with "To Normal or No Change" then participant was counted under "To Low" and/or "To High". If participant had values which belong only to "To Normal or No Change" then participant was counted under "To Normal or No Change" only. Any Time Post-Baseline values have been presented.

End point type	Primary
----------------	---------

End point timeframe:

Baseline, from Week 20 and up to Week 80

Notes:

[32] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There are no statistical data to report.

<b>End point values</b>	Part B: Mepolizumab 40 mg SC	Part B: Mepolizumab 100 mg SC	Part B: Mepolizumab 40/100 mg SC	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	16 <sup>[33]</sup>	10 <sup>[34]</sup>	4 <sup>[35]</sup>	
Units: Participants				
Basophils; To Low	0	0	0	
Basophils; To Normal or No Change	16	10	4	
Basophils; To High	0	0	0	
Eosinophils; To Low	11	6	3	
Eosinophils; To Normal or No Change	5	4	0	
Eosinophils; To High	0	0	1	
MCH; To Low	0	1	0	
MCH; To Normal or No Change	16	9	4	
MCH; To High	0	0	0	
MCHC; To Low	0	1	0	
MCHC; To Normal or No Change	16	9	4	
MCHC; To High	0	0	0	
MCV; To Low	0	1	0	
MCV; To Normal or No Change	16	9	4	
MCV; To High	0	0	0	
Erythrocytes; To Low	0	0	0	
Erythrocytes; To Normal or No Change	15	8	3	
Erythrocytes; To High	1	2	1	
Hematocrit; To Low	0	2	0	
Hematocrit; To Normal or No Change	16	7	4	
Hematocrit; To High	0	1	0	
Hgb; To Low	0	1	0	
Hgb; To Normal or No Change	16	8	4	
Hgb; To High	0	1	0	
Leukocytes; To Low	5	2	1	
Leukocytes; To Normal or No Change	11	7	2	
Leukocytes; To High	0	1	1	
Lymphocytes; To Low	0	0	0	
Lymphocytes; To Normal or No Change	15	9	2	
Lymphocytes; To High	1	1	2	
Monocytes; To Low	6	2	1	
Monocytes; To Normal or No Change	10	8	3	
Monocytes; To High	0	0	0	
Neutrophils; To Low	3	2	2	
Neutrophils; To Normal or No Change	13	5	1	
Neutrophils; To High	0	3	1	
Platelets; To Low	0	0	0	
Platelets; To Normal or No Change	15	10	4	
Platelets; To High	1	0	0	
Ret/Ery; To Low	2	3	1	

Ret/Ery; To Normal or No Change	12	7	3	
Ret/Ery;To High	2	0	0	

Notes:

[33] - Safety Population

[34] - Safety Population

[35] - Safety Population

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of participants with abnormal findings for urinalysis parameters in Part B

End point title	Number of participants with abnormal findings for urinalysis parameters in Part B <sup>[36]</sup>
-----------------	---

End point description:

Urine samples were collected from participants at indicated time points for analysis of urinalysis parameters including Specific gravity and potential of hydrogen (pH) of urine, presence of glucose, protein, blood and ketones in urine by dipstick test. Microscopic examination was performed if blood or protein was abnormal. Only those participants with data available at the specified time points were analyzed.

End point type	Primary
----------------	---------

End point timeframe:

From Week 20 and up to Week 72

Notes:

[36] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There are no statistical data to report.

End point values	Part B: Mepolizumab 40 mg SC	Part B: Mepolizumab 100 mg SC	Part B: Mepolizumab 40/100 mg SC	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	10 <sup>[37]</sup>	9 <sup>[38]</sup>	1 <sup>[39]</sup>	
Units: Participants	7	6	0	

Notes:

[37] - Safety Population

[38] - Safety Population

[39] - Safety Population

## Statistical analyses

No statistical analyses for this end point

### Secondary: Body weight-adjusted apparent clearance of Mepolizumab for Part A

End point title	Body weight-adjusted apparent clearance of Mepolizumab for Part A
-----------------	---

End point description:

PK samples were collected at pre-dose on Weeks 4 and 8; and at Week 9, 12, 16 and 20 post-dose. The body weight-adjusted apparent clearance was compared between adults and participants aged 6 to 11 years old with severe eosinophilic asthma when mepolizumab was administered subcutaneously. Point estimate and 90% confidence interval (CI) for participants aged 6 to 11 years (centered to a mean bodyweight of 70 kg) was compared with the historic adult estimated body-weight adjusted clearance of 0.22 Liter (L)/day, around which a proposed 80-125% interval was applied i.e. 0.18-0.28 L/day. Assuming an absolute bioavailability of 75% this corresponds to an apparent clearance of 0.29 L/day with the proposed 80% to 125% interval of 0.23 to 0.36 L/day. Note the average bodyweight of 70kg (mean body weight observed in adults) was not observed in the study.

End point type	Secondary
End point timeframe:	
Pre-dose on Weeks 4 and 8; Weeks 9, 12, 16 and 20 post-dose	

<b>End point values</b>	Part A: Mepolizumab SC			
Subject group type	Subject analysis set			
Number of subjects analysed	36 <sup>[40]</sup>			
Units: L per day				
arithmetic mean (confidence interval 90%)				
Weight 70kg	0.1968 (0.1694 to 0.2241)			
Weight 50kg	0.1481 (0.1348 to 0.1614)			
Weight 27kg	0.0880 (0.0828 to 0.0932)			

Notes:

[40] - PK Population

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in Asthma Control Questionnaire-7 (ACQ-7) at Week 12 in Part A

End point title	Change from Baseline in Asthma Control Questionnaire-7 (ACQ-7) at Week 12 in Part A
-----------------	---

End point description:

ACQ-7 is a simple questionnaire to measure the adequacy of asthma control and change in asthma control which occurs either spontaneously or a result of treatment. The ACQ-7 uses a 7-point scale (0=no impairment, 6= maximum impairment for symptoms and rescue use; and 7= category for forced expiratory volume in 1 second [FEV1]%). The instrument has a reported high test-retest reproducibility with an intraclass correlation coefficient =0.90. The minimally important change in score is 0.5. Baseline was defined as the latest value recorded prior to the first dose of mepolizumab. Change from Baseline was calculated as score obtained at Week 12 minus Baseline Score. Pharmacodynamic Outcome (PDo) Population included all participants who received at least one dose of mepolizumab beginning at Visit 2 and having at least one Part A assessment of pharmacodynamic outcomes. Only those participants with data available at specific time point were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Week 12

<b>End point values</b>	Part A: Mepolizumab 40 mg SC	Part A: Mepolizumab 100 mg SC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	23 <sup>[41]</sup>	10 <sup>[42]</sup>		
Units: Scores on a scale				
arithmetic mean (standard deviation)				
Scores on a scale	-0.414 (± 1.1354)	0.082 (± 1.3432)		

Notes:

[41] - PDo Population

[42] - PDo Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in Asthma Control Questionnaire-7 (ACQ-7) at Weeks 4,8,16 and 20 in Part A

End point title	Change from Baseline in Asthma Control Questionnaire-7 (ACQ-7) at Weeks 4,8,16 and 20 in Part A
-----------------	---

End point description:

ACQ-7 is a simple questionnaire to measure the adequacy of asthma control and change in asthma control which occurs either spontaneously or a result of treatment. The ACQ-7 uses a 7-point scale (0=no impairment, 6= maximum impairment for symptoms and rescue use; and 7 = category for FEV1%). The instrument has a reported high test-retest reproducibility with an intraclass correlation coefficient =0.90. The minimally important change in score is 0.5. Baseline was defined as the latest value recorded prior to the first dose of mepolizumab. Change from Baseline was calculated as score obtained at the indicated time point minus Baseline Score. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Weeks 4,8,16 and 20

<b>End point values</b>	Part A: Mepolizumab 40 mg SC	Part A: Mepolizumab 100 mg SC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26 <sup>[43]</sup>	10 <sup>[44]</sup>		
Units: Scores on a scale				
arithmetic mean (standard deviation)				
Week 4, n=26, 10	-0.548 (± 1.1351)	-0.473 (± 0.9607)		
Week 8, n=26, 10	-0.652 (± 1.2270)	-0.302 (± 1.2445)		
Week 16, n=23, 10	-0.154 (± 1.2336)	-0.087 (± 1.2541)		
Week 20, n=24, 10	-0.261 (± 1.2303)	-0.088 (± 1.0632)		

Notes:

[43] - PDo Population

[44] - PDo Population

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in Childhood Asthma Control Test (C-ACT) at Week 12 for Part A

End point title	Change from Baseline in Childhood Asthma Control Test (C-ACT) at Week 12 for Part A
-----------------	---

End point description:

The C-ACT assesses asthma control in children 4-11 years of age. The C-ACT is a 7-question, 2-part questionnaire, with items 1 to 4 were completed by the child (with assistance from a caregiver, as needed) and items 5 to 7 were completed by the caregiver. A total sum score based upon responses to all items was calculated to provide an overall measure of asthma control. The derived C-ACT score ranges from 0 (maximum impairment) to 27 (no impairment), where higher scores represent a better outcome. Baseline was defined as the latest value recorded prior to the first dose of mepolizumab. Change from Baseline was calculated as score obtained at Week 12 minus Baseline Score.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Week 12

End point values	Part A: Mepolizumab 40 mg SC	Part A: Mepolizumab 100 mg SC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	22 <sup>[45]</sup>	10 <sup>[46]</sup>		
Units: Scores on a scale				
arithmetic mean (standard deviation)				
Scores on a scale	2.1 (± 4.45)	-0.3 (± 5.19)		

Notes:

[45] - PDo Population

[46] - PDo Population

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in C-ACT at Weeks 4,8,16 and 20 in Part A

End point title	Change from Baseline in C-ACT at Weeks 4,8,16 and 20 in Part A
-----------------	--

End point description:

The C-ACT assesses asthma control in children 4-11 years of age. The C-ACT is a 7-question, 2-part questionnaire, with items 1 to 4 were completed by the child (with assistance from a caregiver, as needed) and items 5 to 7 were completed by the caregiver. A total sum score based upon responses to all items was calculated to provide an overall measure of asthma control. The derived C-ACT score ranges from 0 (maximum impairment) to 27 (no impairment), where higher scores represent a better outcome. Baseline was defined as the latest value recorded prior to the first dose of mepolizumab. Change from Baseline was calculated as score obtained at the indicated time point minus Baseline Score. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Weeks 4, 8, 16, and 20

<b>End point values</b>	Part A: Mepolizumab 40 mg SC	Part A: Mepolizumab 100 mg SC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26 <sup>[47]</sup>	10 <sup>[48]</sup>		
Units: Scores on a scale				
arithmetic mean (standard deviation)				
Week 4, n=26, 10	1.8 (± 4.19)	2.4 (± 4.55)		
Week 8, n=26, 10	3.0 (± 5.77)	1.5 (± 4.28)		
Week 16, n=23, 10	1.5 (± 4.62)	-0.7 (± 5.19)		
Week 20, n=24, 10	1.0 (± 4.23)	0.9 (± 4.28)		

Notes:

[47] - PDo Population

[48] - PDo Population

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with treatment emergent SAEs and non-SAEs in Part A

End point title	Number of participants with treatment emergent SAEs and non-SAEs in Part A
-----------------	--

End point description:

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinemia were categorized as SAE. Participants who received any of the study treatment and had any on-treatment AE or SAE (defined as events occurring from the first dose until 28 days after the last dose of mepolizumab) were considered for analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 20

<b>End point values</b>	Part A: Mepolizumab 40 mg SC	Part A: Mepolizumab 100 mg SC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26 <sup>[49]</sup>	10 <sup>[50]</sup>		
Units: Participants				
Any non-SAE	18	6		
Any SAE	5	1		

Notes:

[49] - Safety Population

[50] - Safety Population

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with any time change from Baseline relative to

## normal range in hematology parameters in Part A

End point title	Number of participants with any time change from Baseline relative to normal range in hematology parameters in Part A
-----------------	---

### End point description:

Blood samples were collected for analysis of basophils, eosinophils, leukocyte, monocyte, neutrophils, lymphocyte, platelet count, MCH, MCHC, Hgb, MCV, erythrocytes, hematocrit, Ret/Ery. The Baseline was the latest value recorded prior to the first dose of mepolizumab. Change from Baseline was defined as value at indicated time point minus Baseline value. Any time post Baseline = all visits (scheduled and unscheduled) post Baseline was considered for this visit derivation. If participant had at least one value for categories "To Low" and/or "To High" along with "To Normal or No Change" then participant was counted under "To Low" and/or "To High". If participant had values which belong only to "To Normal or No Change" then participant was counted under "To Normal or No Change" only. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). Any Time Post-Baseline values have been presented.

End point type	Secondary
----------------	-----------

### End point timeframe:

Baseline and up to Week 20

End point values	Part A: Mepolizumab 40 mg SC	Part A: Mepolizumab 100 mg SC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26 <sup>[51]</sup>	10 <sup>[52]</sup>		
Units: Participants				
Basophils; To low, n=26, 10	0	0		
Basophils; To Normal or No Change n=26, 10	25	10		
Basophils; To high n=26, 10	1	0		
Eosinophils; To low n=26, 10	15	6		
Eosinophils, To Normal or No Change n=26, 10	10	4		
Eosinophils, To high n=26, 10	1	0		
Leukocyte, To low n=26, 10	8	2		
Leukocyte, To Normal or No Change n=26, 10	17	8		
Leukocyte, To high n=26, 10	1	0		
Monocyte, To low n=26, 10	6	3		
Monocyte, To Normal or No Change n=26, 10	19	7		
Monocyte, To high n=26, 10	1	0		
Neutrophils, To low n=26, 10	8	3		
Neutrophils, To Normal or No Change n=26, 10	16	7		
Neutrophils, To high n=26, 10	2	0		
Lymphocyte, To low n=26, 10	4	1		
Lymphocyte, To Normal or No Change n=26, 10	20	8		
Lymphocyte, To high n=26, 10	2	1		
Platelet count, To low n=25, 10	0	1		
Platelet count, To Normal or No change n=25,10	22	9		
Platelet count, To high n=25, 10	3	0		
MCH, To low n=26, 10	2	0		
MCH, To Normal or No Change n=26, 10	24	10		

MCH, To high n=26, 10	0	0		
MCHC, To low n=26, 10	1	1		
MCHC, To Normal or No Change n=26, 10	25	9		
MCHC, To high n=26, 10	0	0		
Hgb, To low n=26, 10	0	1		
Hgb, To Normal or No Change n=26, 10	26	9		
Hgb, To high n=26, 10	0	0		
MCV, To low n=26, 10	2	0		
MCV, To Normal or No Change n=26, 10	24	10		
MCV, To high n=26, 10	0	0		
Erythrocytes, To low n=26, 10	0	0		
Erythrocytes, To Normal or No Change n=26, 10	21	8		
Erythrocytes, To high n=26, 10	5	2		
Hematocrit, To low n=26, 10	0	2		
Hematocrit, To Normal or No Change n=26, 10	26	8		
Hematocrit, To high n=26, 10	0	0		
Ret/Ery, To low n=26, 10	8	1		
Ret/Ery, To Normal or No change n=26, 10	15	9		
Ret/Ery, To high n=26, 10	3	0		

Notes:

[51] - Safety Population

[52] - Safety Population

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with any time change from Baseline relative to normal range in clinical chemistry parameters in Part A

End point title	Number of participants with any time change from Baseline relative to normal range in clinical chemistry parameters in Part A
-----------------	---

End point description:

Blood samples were collected for analysis of ALT, ALP, AST, GGT, albumin, protein, total bilirubin, creatinine, direct bilirubin, urate, calcium, CO<sub>2</sub>, chloride, glucose, potassium, sodium and urea. The Baseline was defined as the latest value recorded prior to the first dose of mepolizumab. Change from Baseline was defined as value at indicated time point minus Baseline value. Any time post Baseline = all visits (including scheduled and unscheduled) post Baseline was considered for this visit derivation. If participant had at least one value for categories "To Low" and/or "To High" along with "To Normal or No Change" then participant was counted under "To Low" and/or "To High". If participant had values which belong only to "To Normal or No Change" then participant was counted under "To Normal or No Change" only. Any Time Post-Baseline valued have been presented.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and up to Week 20

<b>End point values</b>	Part A: Mepolizumab 40 mg SC	Part A: Mepolizumab 100 mg SC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26 <sup>[53]</sup>	10 <sup>[54]</sup>		
Units: Participants				
ALT, To low	0	0		
ALT, To Normal or No Change	26	10		
ALT, To high	0	0		
AST, To low	0	0		
AST, To Normal or No Change	26	10		
AST, To high	0	0		
ALP, To low	0	0		
ALP, To Normal or No Change	26	10		
ALP, To high	0	0		
GGT, To low	0	0		
GGT, To Normal or No Change	26	10		
GGT, To high	0	0		
Albumin, To low	0	0		
Albumin, To Normal or No Change	22	10		
Albumin, To high	4	0		
Protein, To low	0	0		
Protein, To Normal or No Change	23	10		
Protein, To high	3	0		
Total bilirubin, To low	0	0		
Total bilirubin, To Normal or No Change	26	10		
Total bilirubin, To high	0	0		
Creatinine, To low	4	1		
Creatinine, To Normal or No Change	22	9		
Creatinine, To high	0	0		
Direct bilirubin, To low	0	0		
Direct bilirubin, To Normal or No Change	26	10		
Direct bilirubin, To high	0	0		
Urate, To low	1	0		
Urate, To Normal or No Change	25	10		
Urate, To high	0	0		
Calcium, To low	0	0		
Calcium, To Normal or No Change	22	8		
Calcium, To high	4	2		
CO2, To low	12	3		
CO2, To Normal or No Change	14	7		
CO2, To high	0	0		
Chloride, To low	0	0		
Chloride, To Normal or No Change	23	9		
Chloride, To high	3	1		
Glucose, To low	2	0		
Glucose, To Normal or No Change	17	8		
Glucose, To high	7	2		
Potassium, To low	0	0		
Potassium, To Normal or No Change	26	10		
Potassium, To high	0	0		
Sodium, To low	0	0		

Sodium, To Normal or No Change	26	10		
Sodium, To high	0	0		
Urea, To low	1	3		
Urea, To Normal or No Change	25	7		
Urea, To high	0	0		

Notes:

[53] - Safety Population

[54] - Safety Population

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with abnormal findings for urinalysis parameters in Part A

End point title	Number of participants with abnormal findings for urinalysis parameters in Part A
-----------------	---

End point description:

Urine samples were collected from participants at indicated time points for analysis of urinalysis parameters including Specific gravity and potential of hydrogen (pH) of urine, presence of glucose, protein, blood and ketones in urine by dipstick test. Microscopic examination was performed if blood or protein was abnormal. Only those participants with data available at the specified time points were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 20

End point values	Part A: Mepolizumab 40 mg SC	Part A: Mepolizumab 100 mg SC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	15 <sup>[55]</sup>	7 <sup>[56]</sup>		
Units: Participants	5	4		

Notes:

[55] - Safety Population

[56] - Safety Population

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with positive anti-mepolizumab binding antibodies and neutralizing antibodies response in Part A

End point title	Number of participants with positive anti-mepolizumab binding antibodies and neutralizing antibodies response in Part A
-----------------	---

End point description:

Blood sample for immunogenicity was collected for anti-mepolizumab binding antibodies and neutralizing antibodies response in Part A at prior to study treatment administration. Number of participants with positive anti-mepolizumab binding antibodies and neutralizing antibodies response was summarized. Participant was considered 'Positive' if they had at least one positive post-baseline assay result. Any Time Post Baseline has been presented, which included all visits (including scheduled and unscheduled) post-baseline was considered for this visit derivation. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Weeks 16 and 20

<b>End point values</b>	Part A: Mepolizumab 40 mg SC	Part A: Mepolizumab 100 mg SC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26 <sup>[57]</sup>	10 <sup>[58]</sup>		
Units: Participants				
Anti-drug antibody,Any time post-baseline,n=25,10	1	1		
Neutralizing antibody,Any time post-baseline,n=1,1	0	0		

Notes:

[57] - Safety Population

[58] - Safety Population

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in sitting SBP and DBP in Part A

End point title | Change from Baseline in sitting SBP and DBP in Part A

End point description:

Sitting blood pressure measurements were performed in Part A at indicated time points. Measurements were done pre-infusion/injection with the participant sitting, having rested in this position for at least 5 minutes before each reading. The Baseline was defined as the latest value recorded prior to the first dose of mepolizumab. Change from Baseline was defined as value at indicated time point minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type | Secondary

End point timeframe:

Baseline and Weeks 4, 8, 9, 12, 16 and 20

<b>End point values</b>	Part A: Mepolizumab 40 mg SC	Part A: Mepolizumab 100 mg SC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26 <sup>[59]</sup>	10 <sup>[60]</sup>		
Units: mmHg				
arithmetic mean (standard deviation)				
Sitting DBP, Week 4, n=26, 10	0.4 (± 5.72)	2.1 (± 3.87)		
Sitting DBP, Week 8, , n=26, 10	-0.4 (± 5.45)	3.4 (± 7.59)		
Sitting DBP, Week 9, , n=22, 10	1.8 (± 9.82)	4.9 (± 9.13)		
Sitting DBP, Week 12, , n=23, 10	1.5 (± 8.88)	0.3 (± 9.98)		
Sitting DBP, Week 20, , n=24, 10	0.7 (± 6.94)	5.1 (± 7.03)		
Sitting DBP, Week 16, , n=23, 10	0.6 (± 6.99)	3.9 (± 7.06)		
Sitting SBP, Week 4, n=26, 10	3.6 (± 9.92)	-1.9 (± 8.81)		
Sitting SBP, Week 8, , n=26, 10	1.8 (± 8.65)	-0.2 (± 6.23)		

Sitting SBP, Week 9, , n=22, 10	2.8 (± 10.39)	-0.2 (± 12.04)		
Sitting SBP, Week 12, , n=23, 10	4.3 (± 9.89)	-2.9 (± 11.10)		
Sitting SBP, Week 16, , n=23, 10	4.3 (± 11.53)	-4.6 (± 9.94)		
Sitting SBP, Week 20, , n=24, 10	5.0 (± 9.21)	1.4 (± 9.91)		

Notes:

[59] - Safety Population

[60] - Safety Population

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in sitting pulse rate in Part A

End point title	Change from Baseline in sitting pulse rate in Part A
-----------------	--

End point description:

Sitting pulse rate measurements was performed in Part A at indicated time points. Measurements were done pre-infusion/injection with the participant sitting, having rested in this position for at least 5 minutes before each reading. The Baseline was defined as the latest value recorded prior to the first dose of mepolizumab. Change from Baseline was defined as value at indicated time point minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Weeks 4, 8, 9, 12, 16 and 20

End point values	Part A: Mepolizumab 40 mg SC	Part A: Mepolizumab 100 mg SC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26 <sup>[61]</sup>	10 <sup>[62]</sup>		
Units: Beats per minute				
arithmetic mean (standard deviation)				
Sitting pulse rate, Week 4, n=26, 10	-4.0 (± 10.91)	-1.1 (± 10.56)		
Sitting pulse rate, Week 8, , n=26, 10	-3.2 (± 9.11)	1.8 (± 7.42)		
Sitting pulse rate, Week 9, , n=22, 10	-2.9 (± 8.31)	2.3 (± 9.33)		
Sitting pulse rate, Week 12, , n=23, 10	-0.8 (± 8.31)	-0.5 (± 10.73)		
Sitting pulse rate, Week 16, , n=23, 10	-0.6 (± 7.65)	3.5 (± 10.20)		
Sitting pulse rate, Week 20, , n=24, 10	-3.9 (± 13.13)	1.8 (± 8.22)		

Notes:

[61] - Safety Population

[62] - Safety Population

## Statistical analyses

No statistical analyses for this end point

### Secondary: Ratio to Baseline in absolute blood eosinophil count at Weeks 32, 44, 56, 68, 72 and 80 for Part B

End point title	Ratio to Baseline in absolute blood eosinophil count at Weeks 32, 44, 56, 68, 72 and 80 for Part B
-----------------	--

End point description:

Blood samples were collected at the indicated time points for the analysis of eosinophil count. Baseline

was defined as the latest value recorded prior to the first dose of mepolizumab in Part A. Ratio to Baseline was calculated as post-dose visit value/Baseline value. The analysis was based on Pharmacodynamic (Blood Eosinophils) (PDe) Population comprised of all participants receiving at least one dose of mepolizumab beginning at Visit 9 and having at least one Part B blood sample taken for blood eosinophil count. 99999 indicates data was not available due to insufficient number of participants. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

End point type	Secondary
End point timeframe:	
Baseline and Weeks 32, 44, 56, 68, 72 and 80	

End point values	Part B: Mepolizumab 40 mg SC	Part B: Mepolizumab 100 mg SC	Part B: Mepolizumab 40/100 mg SC	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	16 <sup>[63]</sup>	10 <sup>[64]</sup>	4 <sup>[65]</sup>	
Units: Ratio of eosinophils in blood				
geometric mean (confidence interval 95%)				
Week 32; n= 15, 10, 4	0.161 (0.100 to 0.259)	0.176 (0.089 to 0.346)	0.072 (0.021 to 0.247)	
Week 44; n= 15, 10, 4	0.157 (0.093 to 0.263)	0.189 (0.090 to 0.398)	0.147 (0.012 to 1.781)	
Week 56; n= 15, 10, 4	0.149 (0.090 to 0.246)	0.172 (0.094 to 0.314)	0.058 (0.015 to 0.220)	
Week 68; n= 14, 10, 4	0.133 (0.078 to 0.227)	0.214 (0.111 to 0.415)	0.108 (0.009 to 1.271)	
Week 72; n = 15, 10, 4	0.148 (0.086 to 0.254)	0.134 (0.064 to 0.279)	0.098 (0.073 to 0.130)	
Week 80; n =9, 7, 0	0.591 (0.245 to 1.429)	0.647 (0.269 to 1.560)	99999 (99999 to 99999)	

Notes:

[63] - PDe Population

[64] - PDe Population

[65] - PDe Population

### Statistical analyses

No statistical analyses for this end point

## Adverse events

---

### Adverse events information

---

Timeframe for reporting adverse events:

On-treatment serious adverse events (SAEs) and non-SAEs were collected in Part A from first Part A dose until 28 days following last Part A dose (up to Week 20) and in Part B from first Part B dose until 28 days following last Part B dose (Up to Week 72).

Adverse event reporting additional description:

Serious adverse events (SAEs) and non-SAEs were collected in members of Safety Population, comprised of all participants who received at least one dose of open label mepolizumab medication.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20.1
--------------------	------

### Reporting groups

Reporting group title	Part A: Mepolizumab 40 mg SC
-----------------------	------------------------------

Reporting group description:

Participants with bodyweight < 40 kilogram (kg) received 0.4 milliliter (mL) of reconstituted mepolizumab subcutaneously every four weeks, in upper arm or thigh directly from the investigator or designee, under medical supervision. Participant's weight at Week 0 (Visit 2) was considered to select dosage in Part A. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product.

Reporting group title	Part A: Mepolizumab 100 mg SC
-----------------------	-------------------------------

Reporting group description:

Participants with bodyweight  $\geq$  40 kg received 1.0 mL of reconstituted mepolizumab subcutaneously every four weeks, in upper arm or thigh directly from the investigator or designee, under medical supervision. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product. On investigator discretion, injected volume was split between two injection sites and was given as 2 injections of 0.5 mL each if required.

Reporting group title	Part B: Mepolizumab 40 mg SC
-----------------------	------------------------------

Reporting group description:

Participants with bodyweight < 40 kg received 0.4 mL of reconstituted mepolizumab subcutaneously every four weeks, in upper arm or thigh directly from the investigator or designee, under medical supervision. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product.

Reporting group title	Part B: Mepolizumab 100 mg SC
-----------------------	-------------------------------

Reporting group description:

Participants with bodyweight  $\geq$  40 kg received 1.0 mL of reconstituted mepolizumab subcutaneously every four weeks, in upper arm or thigh directly from the investigator or designee, under medical supervision. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product. On investigator discretion, injected volume was split between two injection sites and was given as 2 injections of 0.5 mL each if required.

Reporting group title	Part B: Mepolizumab 40/100 mg SC
-----------------------	----------------------------------

Reporting group description:

Participants received either 0.4 mL or 1.0 mL of reconstituted mepolizumab depending upon the bodyweight, administered subcutaneously every four weeks, in upper arm or thigh directly from the investigator or designee, under medical supervision. Prior to administration, each vial of mepolizumab were reconstituted and swirled gently to enable complete dissolution of the product. Participants enrolled to <40 kg at Visit 9 (Week 20) were summarized in the 40/100 mg SC group if they had weight  $\geq$ 40 kg at any subsequent visit.

<b>Serious adverse events</b>	Part A: Mepolizumab 40 mg SC	Part A: Mepolizumab 100 mg SC	Part B: Mepolizumab 40 mg SC
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 26 (19.23%)	1 / 10 (10.00%)	4 / 16 (25.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Nervous system disorders			
Dizziness			
subjects affected / exposed	1 / 26 (3.85%)	0 / 10 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	1 / 26 (3.85%)	0 / 10 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	1 / 26 (3.85%)	0 / 10 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	1 / 26 (3.85%)	0 / 10 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic shock			
subjects affected / exposed	0 / 26 (0.00%)	0 / 10 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	1 / 26 (3.85%)	0 / 10 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			

Asthma			
subjects affected / exposed	3 / 26 (11.54%)	0 / 10 (0.00%)	2 / 16 (12.50%)
occurrences causally related to treatment / all	1 / 3	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 26 (0.00%)	0 / 10 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 26 (3.85%)	0 / 10 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cellulitis			
subjects affected / exposed	1 / 26 (3.85%)	0 / 10 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	1 / 26 (3.85%)	1 / 10 (10.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 26 (0.00%)	0 / 10 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Part B: Mepolizumab 100 mg SC	Part B: Mepolizumab 40/100 mg SC	
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 10 (20.00%)	1 / 4 (25.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Nervous system disorders			
Dizziness			

subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Headache			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Anaphylactic shock			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	2 / 10 (20.00%)	1 / 4 (25.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epistaxis			

subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Musculoskeletal and connective tissue disorders</b>			
Back pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Infections and infestations</b>			
Cellulitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 4 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 3 %

<b>Non-serious adverse events</b>	Part A: Mepolizumab 40 mg SC	Part A: Mepolizumab 100 mg SC	Part B: Mepolizumab 40 mg SC
<b>Total subjects affected by non-serious adverse events</b>			
subjects affected / exposed	18 / 26 (69.23%)	6 / 10 (60.00%)	15 / 16 (93.75%)
<b>Vascular disorders</b>			
Orthostatic hypotension			
subjects affected / exposed	0 / 26 (0.00%)	0 / 10 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
<b>General disorders and administration site conditions</b>			
Adverse food reaction			

subjects affected / exposed	0 / 26 (0.00%)	0 / 10 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Fatigue			
subjects affected / exposed	0 / 26 (0.00%)	0 / 10 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Injection site reaction			
subjects affected / exposed	5 / 26 (19.23%)	0 / 10 (0.00%)	0 / 16 (0.00%)
occurrences (all)	7	0	0
Pain			
subjects affected / exposed	1 / 26 (3.85%)	0 / 10 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Pyrexia			
subjects affected / exposed	1 / 26 (3.85%)	0 / 10 (0.00%)	1 / 16 (6.25%)
occurrences (all)	1	0	1
Xerosis			
subjects affected / exposed	0 / 26 (0.00%)	0 / 10 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	1 / 26 (3.85%)	0 / 10 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Seasonal allergy			
subjects affected / exposed	0 / 26 (0.00%)	0 / 10 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	1 / 26 (3.85%)	0 / 10 (0.00%)	2 / 16 (12.50%)
occurrences (all)	2	0	4
Cough			
subjects affected / exposed	1 / 26 (3.85%)	0 / 10 (0.00%)	1 / 16 (6.25%)
occurrences (all)	1	0	1
Dysphonia			
subjects affected / exposed	0 / 26 (0.00%)	1 / 10 (10.00%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Epistaxis			

subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 10 (0.00%) 0	2 / 16 (12.50%) 2
Fibrinous bronchitis subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 10 (0.00%) 0	0 / 16 (0.00%) 0
Nasal congestion subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	1 / 10 (10.00%) 1	0 / 16 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	2 / 26 (7.69%) 2	0 / 10 (0.00%) 0	0 / 16 (0.00%) 0
Pharyngeal erythema subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	1 / 10 (10.00%) 1	0 / 16 (0.00%) 0
Productive cough subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	1 / 10 (10.00%) 2	0 / 16 (0.00%) 0
Upper respiratory tract inflammation subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 10 (0.00%) 0	0 / 16 (0.00%) 0
Wheezing subjects affected / exposed occurrences (all)	2 / 26 (7.69%) 3	1 / 10 (10.00%) 1	0 / 16 (0.00%) 0
Throat irritation subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	1 / 16 (6.25%) 1
Psychiatric disorders			
Aggression subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	2 / 16 (12.50%) 3
Anxiety subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	1 / 16 (6.25%) 1
Depressed mood subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	1 / 16 (6.25%) 1

Enuresis subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	1 / 16 (6.25%) 1
Investigations			
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	1 / 10 (10.00%) 1	0 / 16 (0.00%) 0
Body temperature increased subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 10 (0.00%) 0	0 / 16 (0.00%) 0
Neutrophil count decreased subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 10 (0.00%) 0	1 / 16 (6.25%) 1
Injury, poisoning and procedural complications			
Ankle fracture subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 10 (0.00%) 0	0 / 16 (0.00%) 0
Contusion subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	1 / 16 (6.25%) 1
Heat stroke subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	1 / 16 (6.25%) 1
Laceration subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	0 / 16 (0.00%) 0
Limb injury subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	0 / 16 (0.00%) 0
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 10 (0.00%) 0	0 / 16 (0.00%) 0
Dizziness postural subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	1 / 10 (10.00%) 1	0 / 16 (0.00%) 0

Headache subjects affected / exposed occurrences (all)	3 / 26 (11.54%) 3	2 / 10 (20.00%) 3	4 / 16 (25.00%) 5
Lethargy subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 10 (0.00%) 0	0 / 16 (0.00%) 0
Orthostatic intolerance subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	0 / 16 (0.00%) 0
Blood and lymphatic system disorders lymphadenopathy subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	0 / 16 (0.00%) 0
Eye disorders Eye pain subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	1 / 16 (6.25%) 1
Eye swelling subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	0 / 16 (0.00%) 0
Eyelid haematoma subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	1 / 16 (6.25%) 1
Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 10 (0.00%) 0	0 / 16 (0.00%) 0
Abdominal pain upper subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 10 (0.00%) 0	2 / 16 (12.50%) 4
Constipation subjects affected / exposed occurrences (all)	2 / 26 (7.69%) 2	0 / 10 (0.00%) 0	1 / 16 (6.25%) 1
Diarrhoea subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	2 / 16 (12.50%) 2
Gastritis			

subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 10 (0.00%) 0	0 / 16 (0.00%) 0
Nausea subjects affected / exposed occurrences (all)	3 / 26 (11.54%) 3	0 / 10 (0.00%) 0	1 / 16 (6.25%) 1
Vomiting subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	1 / 10 (10.00%) 1	0 / 16 (0.00%) 0
Hepatobiliary disorders Hepatic function abnormal subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	1 / 16 (6.25%) 1
Skin and subcutaneous tissue disorders Acne subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	1 / 10 (10.00%) 1	0 / 16 (0.00%) 0
Dermatitis allergic subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	1 / 10 (10.00%) 1	0 / 16 (0.00%) 0
Dry skin subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	1 / 10 (10.00%) 1	0 / 16 (0.00%) 0
Rash subjects affected / exposed occurrences (all)	2 / 26 (7.69%) 4	0 / 10 (0.00%) 0	2 / 16 (12.50%) 2
Eczema subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	2 / 16 (12.50%) 2
Erythema subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	0 / 16 (0.00%) 0
Haemorrhage subcutaneous subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	1 / 16 (6.25%) 1
Pruritus			

subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	1 / 16 (6.25%) 1
Rash generalised subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	0 / 16 (0.00%) 0
Urticaria subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	1 / 16 (6.25%) 1
Dermatitis atopic subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	1 / 16 (6.25%) 1
Renal and urinary disorders Urinary retention subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 10 (0.00%) 0	0 / 16 (0.00%) 0
Endocrine disorders Adrenal suppression subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	0 / 16 (0.00%) 0
Musculoskeletal and connective tissue disorders Musculoskeletal pain subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 10 (0.00%) 0	0 / 16 (0.00%) 0
Arthritis subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	1 / 16 (6.25%) 1
Back pain subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	2 / 16 (12.50%) 2
Joint swelling subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	0 / 16 (0.00%) 0
Pain in extremity subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 10 (0.00%) 0	0 / 16 (0.00%) 0
Infections and infestations			

Acute sinusitis			
subjects affected / exposed	1 / 26 (3.85%)	0 / 10 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Bronchitis			
subjects affected / exposed	1 / 26 (3.85%)	0 / 10 (0.00%)	5 / 16 (31.25%)
occurrences (all)	1	0	5
Conjunctivitis			
subjects affected / exposed	0 / 26 (0.00%)	0 / 10 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Croup infectious			
subjects affected / exposed	1 / 26 (3.85%)	0 / 10 (0.00%)	1 / 16 (6.25%)
occurrences (all)	1	0	1
Ear infection			
subjects affected / exposed	0 / 26 (0.00%)	0 / 10 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Eczema infected			
subjects affected / exposed	1 / 26 (3.85%)	0 / 10 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Empyema			
subjects affected / exposed	0 / 26 (0.00%)	0 / 10 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	1 / 26 (3.85%)	0 / 10 (0.00%)	2 / 16 (12.50%)
occurrences (all)	1	0	2
Gastroenteritis norovirus			
subjects affected / exposed	0 / 26 (0.00%)	0 / 10 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Nasopharyngitis			
subjects affected / exposed	3 / 26 (11.54%)	1 / 10 (10.00%)	3 / 16 (18.75%)
occurrences (all)	3	1	3
Oral herpes			
subjects affected / exposed	0 / 26 (0.00%)	1 / 10 (10.00%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Otitis media acute			
subjects affected / exposed	1 / 26 (3.85%)	0 / 10 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0

Pharyngitis			
subjects affected / exposed	1 / 26 (3.85%)	0 / 10 (0.00%)	3 / 16 (18.75%)
occurrences (all)	1	0	3
Pneumonia			
subjects affected / exposed	1 / 26 (3.85%)	0 / 10 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Respiratory tract infection viral			
subjects affected / exposed	1 / 26 (3.85%)	0 / 10 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Rhinitis			
subjects affected / exposed	0 / 26 (0.00%)	1 / 10 (10.00%)	0 / 16 (0.00%)
occurrences (all)	0	2	0
Sinusitis			
subjects affected / exposed	1 / 26 (3.85%)	1 / 10 (10.00%)	0 / 16 (0.00%)
occurrences (all)	1	1	0
Tinea infection			
subjects affected / exposed	1 / 26 (3.85%)	0 / 10 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Upper respiratory tract infection			
subjects affected / exposed	2 / 26 (7.69%)	1 / 10 (10.00%)	2 / 16 (12.50%)
occurrences (all)	2	1	7
Viral upper respiratory tract infection			
subjects affected / exposed	2 / 26 (7.69%)	0 / 10 (0.00%)	2 / 16 (12.50%)
occurrences (all)	2	0	4
Wound infection			
subjects affected / exposed	0 / 26 (0.00%)	1 / 10 (10.00%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Gastroenteritis viral			
subjects affected / exposed	0 / 26 (0.00%)	0 / 10 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Hordeolum			
subjects affected / exposed	0 / 26 (0.00%)	0 / 10 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Impetigo			
subjects affected / exposed	0 / 26 (0.00%)	0 / 10 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1

Influenza			
subjects affected / exposed	0 / 26 (0.00%)	0 / 10 (0.00%)	3 / 16 (18.75%)
occurrences (all)	0	0	4
Lower respiratory tract infection			
subjects affected / exposed	0 / 26 (0.00%)	0 / 10 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Paronychia			
subjects affected / exposed	0 / 26 (0.00%)	0 / 10 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Tracheitis			
subjects affected / exposed	0 / 26 (0.00%)	0 / 10 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Viral pharyngitis			
subjects affected / exposed	0 / 26 (0.00%)	0 / 10 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Pneumonia Bacterial			
subjects affected / exposed	0 / 26 (0.00%)	0 / 10 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Hypercholesterolaemia			
subjects affected / exposed	0 / 26 (0.00%)	1 / 10 (10.00%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Hyperglycaemia			
subjects affected / exposed	0 / 26 (0.00%)	1 / 10 (10.00%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Hypertriglyceridaemia			
subjects affected / exposed	0 / 26 (0.00%)	1 / 10 (10.00%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Decreased appetite			
subjects affected / exposed	0 / 26 (0.00%)	0 / 10 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Hypoglycaemia			
subjects affected / exposed	0 / 26 (0.00%)	0 / 10 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1

<b>Non-serious adverse events</b>	Part B: Mepolizumab 100 mg SC	Part B: Mepolizumab 40/100 mg SC	
-----------------------------------	----------------------------------	-------------------------------------	--

Total subjects affected by non-serious adverse events subjects affected / exposed	8 / 10 (80.00%)	4 / 4 (100.00%)	
Vascular disorders Orthostatic hypotension subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 4 (0.00%) 0	
General disorders and administration site conditions Adverse food reaction subjects affected / exposed occurrences (all)  Fatigue subjects affected / exposed occurrences (all)  Injection site reaction subjects affected / exposed occurrences (all)  Pain subjects affected / exposed occurrences (all)  Pyrexia subjects affected / exposed occurrences (all)  Xerosis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0  0 / 10 (0.00%) 0  0 / 10 (0.00%) 0  0 / 10 (0.00%) 0  0 / 10 (0.00%) 0  1 / 10 (10.00%) 1  1 / 10 (10.00%) 1	0 / 4 (0.00%) 0  0 / 4 (0.00%) 0  0 / 4 (0.00%) 0  0 / 4 (0.00%) 0  0 / 4 (0.00%) 0	
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)  Seasonal allergy subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0  0 / 10 (0.00%) 0	0 / 4 (0.00%) 0  0 / 4 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders Asthma subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 4 (0.00%) 0	

Cough			
subjects affected / exposed	2 / 10 (20.00%)	0 / 4 (0.00%)	
occurrences (all)	3	0	
Dysphonia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Epistaxis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Fibrinous bronchitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Nasal congestion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Oropharyngeal pain			
subjects affected / exposed	1 / 10 (10.00%)	0 / 4 (0.00%)	
occurrences (all)	1	0	
Pharyngeal erythema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Productive cough			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Upper respiratory tract inflammation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Wheezing			
subjects affected / exposed	1 / 10 (10.00%)	0 / 4 (0.00%)	
occurrences (all)	2	0	
Throat irritation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Psychiatric disorders			
Aggression			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 4 (0.00%) 0	
Anxiety subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 4 (0.00%) 0	
Depressed mood subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 4 (0.00%) 0	
Enuresis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 4 (0.00%) 0	
Investigations Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 4 (0.00%) 0	
Body temperature increased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 4 (0.00%) 0	
Neutrophil count decreased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 4 (0.00%) 0	
Injury, poisoning and procedural complications Ankle fracture subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 4 (0.00%) 0	
Contusion subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 4 (0.00%) 0	
Heat stroke subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 4 (0.00%) 0	
Laceration subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 4 (0.00%) 0	
Limb injury			

subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 4 (0.00%) 0	
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Dizziness postural			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Headache			
subjects affected / exposed	3 / 10 (30.00%)	1 / 4 (25.00%)	
occurrences (all)	9	1	
Lethargy			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Orthostatic intolerance			
subjects affected / exposed	0 / 10 (0.00%)	1 / 4 (25.00%)	
occurrences (all)	0	1	
Blood and lymphatic system disorders			
lymphadenopathy			
subjects affected / exposed	1 / 10 (10.00%)	0 / 4 (0.00%)	
occurrences (all)	1	0	
Eye disorders			
Eye pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Eye swelling			
subjects affected / exposed	1 / 10 (10.00%)	0 / 4 (0.00%)	
occurrences (all)	2	0	
Eyelid haematoma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 10 (0.00%)	1 / 4 (25.00%)	
occurrences (all)	0	1	
Abdominal pain upper			

subjects affected / exposed	1 / 10 (10.00%)	0 / 4 (0.00%)	
occurrences (all)	2	0	
Constipation			
subjects affected / exposed	0 / 10 (0.00%)	1 / 4 (25.00%)	
occurrences (all)	0	1	
Diarrhoea			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Gastritis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Nausea			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Vomiting			
subjects affected / exposed	1 / 10 (10.00%)	0 / 4 (0.00%)	
occurrences (all)	1	0	
Hepatobiliary disorders			
Hepatic function abnormal			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Dermatitis allergic			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Dry skin			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Rash			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Eczema			

subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 4 (0.00%) 0	
Erythema subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 2	0 / 4 (0.00%) 0	
Haemorrhage subcutaneous subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 4 (0.00%) 0	
Pruritus subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 4 (0.00%) 0	
Rash generalised subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 4 (0.00%) 0	
Urticaria subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 4 (0.00%) 0	
Dermatitis atopic subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 4 (0.00%) 0	
Renal and urinary disorders Urinary retention subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 4 (0.00%) 0	
Endocrine disorders Adrenal suppression subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 4 (25.00%) 1	
Musculoskeletal and connective tissue disorders Musculoskeletal pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 4 (0.00%) 0	
Arthritis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 4 (0.00%) 0	
Back pain			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 4 (0.00%) 0	
Joint swelling subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 4 (0.00%) 0	
Pain in extremity subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 4 (0.00%) 0	
<b>Infections and infestations</b>			
Acute sinusitis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 4 (0.00%) 0	
Bronchitis subjects affected / exposed occurrences (all)	3 / 10 (30.00%) 3	1 / 4 (25.00%) 1	
Conjunctivitis subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 4 (0.00%) 0	
Croup infectious subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 4 (0.00%) 0	
Ear infection subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	1 / 4 (25.00%) 1	
Eczema infected subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 4 (0.00%) 0	
Empyema subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 4 (25.00%) 1	
Gastroenteritis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 4 (0.00%) 0	
Gastroenteritis norovirus subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 4 (0.00%) 0	

Nasopharyngitis		
subjects affected / exposed	1 / 10 (10.00%)	2 / 4 (50.00%)
occurrences (all)	2	6
Oral herpes		
subjects affected / exposed	1 / 10 (10.00%)	0 / 4 (0.00%)
occurrences (all)	2	0
Otitis media acute		
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0
Pharyngitis		
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0
Pneumonia		
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0
Respiratory tract infection viral		
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0
Rhinitis		
subjects affected / exposed	1 / 10 (10.00%)	1 / 4 (25.00%)
occurrences (all)	2	1
Sinusitis		
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0
Tinea infection		
subjects affected / exposed	1 / 10 (10.00%)	0 / 4 (0.00%)
occurrences (all)	1	0
Upper respiratory tract infection		
subjects affected / exposed	2 / 10 (20.00%)	1 / 4 (25.00%)
occurrences (all)	7	1
Viral upper respiratory tract infection		
subjects affected / exposed	0 / 10 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	2
Wound infection		
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0

Gastroenteritis viral			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Hordeolum			
subjects affected / exposed	1 / 10 (10.00%)	0 / 4 (0.00%)	
occurrences (all)	1	0	
Impetigo			
subjects affected / exposed	1 / 10 (10.00%)	0 / 4 (0.00%)	
occurrences (all)	1	0	
Influenza			
subjects affected / exposed	0 / 10 (0.00%)	1 / 4 (25.00%)	
occurrences (all)	0	1	
Lower respiratory tract infection			
subjects affected / exposed	1 / 10 (10.00%)	0 / 4 (0.00%)	
occurrences (all)	1	0	
Paronychia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Tracheitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Viral pharyngitis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 4 (25.00%)	
occurrences (all)	0	1	
Pneumonia Bacterial			
subjects affected / exposed	0 / 10 (0.00%)	1 / 4 (25.00%)	
occurrences (all)	0	1	
Metabolism and nutrition disorders			
Hypercholesterolaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Hyperglycaemia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 4 (25.00%)	
occurrences (all)	0	1	
Hypertriglyceridaemia			

subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Decreased appetite			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	
Hypoglycaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
10 June 2015	<ul style="list-style-type: none"><li>- Addition of the C-ACT questionnaire to assess asthma control</li><li>- To allow of the use of the ACQ tool to be administered in each country for which there is a validated translation available</li><li>- Use of the Global Lung Function Initiative 2012 equations by Quanjer (2012) to estimate FEV1 predicted values</li><li>- To add a copy of the ACQ-7, ACQ-IA and C-ACT questionnaire</li><li>- To clarify that blood samples will be stored for up to 15 years after the end of the study.</li><li>- To correct few typographical errors and few minor changes</li></ul>
30 September 2015	<ul style="list-style-type: none"><li>- To change the details of the Primary and Secondary Medical Monitors for the study.</li><li>- To permit extended mepolizumab treatment for a minimum of 52 weeks upon completion of the pharmacokinetic/pharmacodynamic phase (Part A) of the protocol.</li><li>- To add long-term safety (52 weeks) as the primary objective for the extended treatment phase (Part B).</li><li>- To add long-term pharmacodynamic response as a secondary objective for the extended treatment phase.</li><li>- To amend Section 9.3.2 to specify a pre-planned interim analyses to report results of the initial pharmacokinetic/pharmacodynamic phase upon completion of all required assessment for all subjects.</li><li>- To add Section 9.5 to define the primary and secondary analysis plans for the extended treatment phase</li></ul>
30 March 2016	<ul style="list-style-type: none"><li>- Protocol Synopsis, Treatment Arms and Duration, Part B Treatment were updated to clarify the design and procedure</li><li>- Section 4 Part A Follow-up: To change "positive neutralizing antibody" to "positive anti-mepolizumab antibody" and to clarify the timeline for obtaining a repeat sample</li><li>- To clarify that subjects should be monitored for 1 hour post-dose during Part A only and thereafter monitoring in Part B will be according to standard practice at the site and to give guidance regarding the capability requirements at site during this monitoring.</li><li>- To clarify that sample size is not determined for Part B and that all subjects completing Part A are eligible for Part B.</li><li>- Changes in inclusion and exclusion criteria</li><li>- Withdrawal/Stopping Criteria: To clarify that the Early Withdrawal Visit should be completed for subjects withdrawing from the study.</li><li>- Permitted Medications and Non-Drug Therapies: To clarify that time of administration of concomitant medications is not required in the electronic case report form. To clarify that rescue medication will be provided for the study. To clarify that oral corticosteroids are permitted during this study and to clarify that baseline inhaled corticosteroids (ICS) and Baseline controller levels should not be changed between screening and Visit 2.</li><li>- Few typographical corrections</li><li>- To correct sample size assumptions, Secondary and Exploratory Analyses assumptions for Part B.</li></ul>
05 May 2016	<ul style="list-style-type: none"><li>- Inclusion Criteria for Part A: To correct an error in Protocol Amendment 03 when text was deleted from Inclusion Criterion 4 in error.</li></ul>

18 January 2017	<ul style="list-style-type: none"> <li>- Protocol Synopsis, Rationale: To clarify that Part B follow-up is not required for subjects transitioning to the long-term access program.</li> <li>- Secondary and Exploratory Endpoints will be measured from Week 0 in Part A instead of Week 20 in Part B:</li> <li>- "Change from Week 20 (Visit 9)" is amended to "Change from Week 0 (Visit 2)" and that Secondary and Exploratory Endpoints will be measured at Week 80 only for subjects that will not transition to the long-term access program.</li> </ul> <p>To clarify that Part B follow-up is not required for subjects transitioning to the long term access program.</p> <ul style="list-style-type: none"> <li>- To clarify the definition of "completed subject" for subjects transitioning to the long-term access program and for those that do not transition.</li> <li>- Treatment After the Completion of Part A and Part B: Updated to include the long-term access program as an option for treatment of subjects after the end of Part B.</li> <li>- To clarify that immunoglobulin E (IgE) total only will be measured for this study.</li> <li>- Sample Size Considerations updated to clarify that the clearance mentioned in the section refers to apparent clearance.</li> </ul> <p>To quote the body-weight adjusted clearance value in adults (instead of the bodyweight-adjusted apparent clearance) and the 80-125% interval around this value, and to provide as additional information the value of the corresponding apparent clearance.</p> <ul style="list-style-type: none"> <li>- Abbreviations and Trademarks: Apparent clearance after extravascular (e.g., subcutaneous) administration added.</li> <li>- Reporting of SAEs to GlaxoSmithKline: clarification made to the point regarding reporting SAEs when the electronic system is down.</li> </ul>
-----------------	---

Notes:

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported